Page 2 - Pharma Companies

Gland Pharma to acquire French firm Cenexi Group for Rs 1,000 crore

Will fund transaction from internal accruals

Zuventus first in world to launch aviptadil for ARDS commercially

Discovered in 1970, the drug was tested on severe Covid-19 patients on DCGI's direction

Aurobindo unit, Evive Biotech ink pact to sell CIN treatment product in US

Aurobindo Pharma on Wednesday said its unit has entered into a licensing pact with Evive Biotech to commercialise Ryzneuta in the US market. The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN). In addition to the US health regulator, Evive's Marketing Authorization Application (MAA), and New Drug Application (NDA) for Ryzneuta are currently under review by European and Chinese regulators. Neutropenia is a common side-effect of chemotherapy and is a condition characterised by low levels of neutrophils, a type of white blood cell that fights infection. The licensing pact has been inked between Evive and Acrotech Biopharma (Acrotech), a New Jersey-based and wholly-owned subsidiary of Aurobindo Pharma USA Inc, Aurobindo Pharma said in a statement. As part of the agreement, Evive will be responsible for the ongoing development, manufacturi

Trying to lock in vendors who don't want to buy from China: Biocon CEO & MD

Siddharth Mittal, CEO & MD, Biocon, elaborates on his plans to grow this business further

Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

Soon, 300 drug formulations to have mandatory bar codes on packages

To curb the menace of spurious medicines, the government is finalising the process of mandating pharmaceutical companies to print bar code on the packages of 300 drug formulations so that information such as manufacturing licence and batch number can be accessed upon scanning. The amendments to Drugs and Cosmetic Rules, 1945 which, once approved, will come into force from May next year. "A sizable of the drugs mentioned in the list are mostly bought over the counter exposing people to the possibility of consuming counterfeit medicines. This amendment aims to prevent supply of fake medicines and ensure improvement in public healthcare," an official source told PTI. "A bar code or QR code will authenticate whether a particular drug is original or not," the official added. The Union health ministry had issued a draft gazette notification regarding the same in June seeking comments and feedback from the public. Based on the comments and further deliberations, the ministry is in the ..

Pharma marketing practices: High-level committee to meet industry on Friday

The UCPMP is voluntary and there is no legal penalty for violating the code

Glenmark Pharma gets US health regulator nod for generic medication

Glenmark Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market Sodium Phenylbutyrate tablets, used in treating urea cycle disorders, in America. The company has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of Horizon Therapeutics' Buphenyl, the Mumbai-based drug maker said in a statement. According to IQVIA sales data for 12-month period ended September 2022, Buphenyl had annual sales of around USD 8.7 million. Glenmark's current portfolio consists of 177 products authorised for distribution in the US marketplace and 46 abbreviated new drug applications (ANDAs) pending approval with the USFDA.

Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales

Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year

Strong US pipeline, sustained growth trajectory main trigger for Dr Reddy's

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

Uncertainty on revenue growth, margin outlook hits Gland Pharma stock

The injectable manufacturing company expects the margin pressure to persist due to cost pressures and negative operating leverage.

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Lupin inks pact to acquire two inhalation brands from Sunovion for $75 mn

Drug maker Lupin on Thursday said it will acquire two inhalation brands from Sunovion Pharmaceuticals Inc for USD 75 million (around Rs 622 crore). The drug firm has inked a pact with US-based Sunovion to acquire Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol. The Mumbai-based firm expects the transaction to be accretive to earnings in the first year. The acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the respiratory therapy area while continuing to provide patients access to these important medicines, Lupin said in a statement. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Xopenex HFA is a short-acting beta2-adrenergic agonist (SABA), indicated for the treatment or prevention of bronchospasm in adults, ...

Marksans Pharma to acquire Tevapharm's bulk formulations business

Drug firm Marksans Pharma on Tuesday said it has inked a pact with Tevapharm India to acquire its Goa-based bulk pharmaceutical formulations business. The company has entered into a business transfer agreement with Tevapharm to acquire its business relating to the manufacture and supply of bulk pharmaceutical formulations as a going concern on a slump sale basis. The drug firm has agreed to retain the site employees with existing terms of employment, Marksans Pharma said in a regulatory filing. The transaction is in cash consideration and expected to be finalised by April 1, 2023, subject to the closing conditions, it said, but did not specify the deal value. Teva's affiliate Watson Pharma will continue to own and operate Tevapharm's other manufacturing site at Verna, Goa, the drug firm added. Marksans will continue to supply Teva's affiliates with certain products until the end of FY23 as part of the agreement, which can be extended further with mutual agreement, it said. "The .

New Jersey-based Amneal Pharma starts mfg operations for Indian market

The firm already has manufacturing units in four Indian cities, all of which are focused on the export market

Top Headlines: Run-up to Budget 2023-24, India Inc's Q2 earnings, and more

The July-September quarter (second quarter, or Q2) of 2022-23 (FY23) could mark the end of the period of an unprecedented rise in India Inc's earnings in the aftermath of the pandemic

Maiden Pharmaceuticals breaks silence on cough syrup deaths in Gambia

The pharma company Maiden Pharmaceuticals has come under scanner after 66 children died in the Gambia after consuming cough syrup produced in India

Udaan to provide medicine delivery to pharmacies every 4-hour

As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities

Centre looking to phase out codeine-based cough syrups, select FDCs

The industry is divided on the issue of phasing out codeine-based cough syrups, which are used by many as intoxicants

DTAB to review 19 fixed-dose combinations drugs, codeine formulations today

CDSCO aims to phase out these combinations and codeine-based drugs in a phased manner